These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26088817)

  • 41. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings.
    Venturini M; Arisi M; Zanca A; Cavazzana I; Gonzàlez S; Franceschini F; Calzavara-Pinton P
    Eur J Dermatol; 2014; 24(3):349-55. PubMed ID: 24721824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor.
    Balzan S; Del Carratore R; Nicolini G; Beffy P; Lubrano V; Forini F; Iervasi G
    J Clin Endocrinol Metab; 2012 May; 97(5):1763-70. PubMed ID: 22419707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.
    Cipriani P; Di Benedetto P; Ruscitti P; Capece D; Zazzeroni F; Liakouli V; Pantano I; Berardicurti O; Carubbi F; Pecetti G; Turricchia S; Alesse E; Iglarz M; Giacomelli R
    J Rheumatol; 2015 Oct; 42(10):1808-16. PubMed ID: 26276964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement.
    Kaji K; Fertig N; Medsger TA; Satoh T; Hoshino K; Hamaguchi Y; Hasegawa M; Lucas M; Schnure A; Ogawa F; Sato S; Takehara K; Fujimoto M; Kuwana M
    Arthritis Care Res (Hoboken); 2014 Apr; 66(4):575-84. PubMed ID: 24023044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells.
    Xiang Y; Matsui T; Matsuo K; Shimada K; Tohma S; Nakamura H; Masuko K; Yudoh K; Nishioka K; Kato T
    Arthritis Rheum; 2007 Jun; 56(6):2018-30. PubMed ID: 17530642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
    Gu Y; Scheuer C; Feng D; Menger MD; Laschke MW
    Anticancer Drugs; 2013 Sep; 24(8):781-91. PubMed ID: 23744558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor.
    Kakigano A; Tomimatsu T; Mimura K; Kanayama T; Fujita S; Minato K; Kumasawa K; Taniguchi Y; Kanagawa T; Endo M; Ishihara T; Namba T; Mizushima T; Kimura T
    Reprod Sci; 2015 Oct; 22(10):1272-80. PubMed ID: 25736325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients.
    Arakawa H; Jinnin M; Muchemwa FC; Makino T; Kajihara I; Makino K; Honda N; Sakai K; Fukushima S; Ihn H
    Exp Dermatol; 2011 Sep; 20(9):764-6. PubMed ID: 21615510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.
    Cipriani P; Guiducci S; Miniati I; Cinelli M; Urbani S; Marrelli A; Dolo V; Pavan A; Saccardi R; Tyndall A; Giacomelli R; Cerinic MM
    Arthritis Rheum; 2007 Jun; 56(6):1994-2004. PubMed ID: 17530639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
    Masui Y; Asano Y; Shibata S; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Rheumatology (Oxford); 2013 Jul; 52(7):1239-44. PubMed ID: 23443327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.
    Avouac J; Clemessy M; Distler JH; Gasc JM; Ruiz B; Vacher-Lavenu MC; Wipff J; Kahan A; Boileau C; Corvol P; Allanore Y
    Rheumatology (Oxford); 2011 Aug; 50(8):1494-504. PubMed ID: 21454305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlations between skin blood perfusion values and nailfold capillaroscopy scores in systemic sclerosis patients.
    Ruaro B; Sulli A; Pizzorni C; Paolino S; Smith V; Cutolo M
    Microvasc Res; 2016 May; 105():119-24. PubMed ID: 26907637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma.
    Klein S; Kretz CC; Ruland V; Stumpf C; Haust M; Hartschuh W; Hartmann M; Enk A; Suri-Payer E; Oberle N; Krammer PH; Kuhn A
    Ann Rheum Dis; 2011 Aug; 70(8):1475-81. PubMed ID: 21097800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1.
    Lemaire R; Burwell T; Sun H; Delaney T; Bakken J; Cheng L; Rebelatto MC; Czapiga M; de-Mendez I; Coyle AJ; Herbst R; Lafyatis R; Connor J
    Arthritis Rheumatol; 2016 Feb; 68(2):473-83. PubMed ID: 26414805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
    Asano Y
    Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis.
    Ichimura Y; Asano Y; Akamata K; Noda S; Taniguchi T; Takahashi T; Toyama T; Tada Y; Sugaya M; Sato S; Kadono T
    Arthritis Rheumatol; 2015 Dec; 67(12):3245-55. PubMed ID: 26245842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.